Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies

Inclusion Criteria: * Patients must have a histologically confirmed diagnosis of B-NHL, T-NHL, or HL; only patients with classical HL must have documented histologic demonstration of CD45+ cells adjacent to the Reed Sternberg cells; patients must have received at least one prior standard systemic therapy with documented recurrent or refractory disease; patients with mantle cell lymphoma (MCL), T-NHL, or other high-risk malignancies may be enrolled/transplanted in complete remission (CR)/first partial remission (PR1) * Creatinine \< 2.0 * Bilirubin \< 1.5 mg/dL * All patients eligible for therapeutic study must have a minimum of \>= 2 x 10\^6 CD34/kg autologous hematopoietic stem cells harvested and cryopreserved * Patients must have an expected survival of \> 60 days and must be free of major infection * Patients are preferred to have either a tumor mass amenable to core needle biopsy during the dosimetry phase, or a measurable tumor mass with at least one site of involvement measuring 2.5 cm in largest dimension on computed tomography (CT) imaging for purposes of planar and/or single-photon emission computed tomography (SPECT)/CT tumor dosimetry Exclusion Criteria: * Circulating human anti-mouse antibody (HAMA), to be determined before each infusion * Systemic anti-lymphoma therapy given in the previous 30 days before the scheduled therapy dose with the exception of rituximab * Inability to understand or give an informed consent * Lymphoma involving the central nervous sy…